Lipid-lowering effect of nattokinase in patients with primary hypercholesterolemia

Acta Cardiologica Sinica

Volumn 25, Issue 1, 2009, Pages 26-30

  Wu, Der Jinn ^a,c   Lin, Cheng Sheng ^b   Lee, Ming Yung ^c  

^a Chung Shan Medicial University Hospital   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

HDL cholesterol; Hypercholesterolemia; LDL cholesterol; Nattokinase

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NATTOKINASE; PLACEBO; PLASMIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 66449133596     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. The Third Report of the National Cholesterol Education Program (NCEP), Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III): final report. Circulation 2002;106:3134-3421
2. Down JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of Air force/ Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622
3. Heart Protection Study Collaborative Group. MIR/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002;360:7-22. (Pubitemid 34756487)
4. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atrovsatatin in hypertensive patients who have average or low-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcome Trial-Lipid-lowering Arm (ASCOT-LIA), a multicentre randomized controlled trial. Lancet 2003;361:1149-1158 (Pubitemid 36398384)
5. Fujita M, Nomura K, Hong K, et al. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean food in Japan. Biochemitry & Biophysics Research Community 1993;197:1340-1347 (Pubitemid 24042769)
6. Sumi H, Hamada H, Tsusgima H, et al. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a typical and popular soybean in the Japanese diet. Experientia 1987;43:1110-1111
7. Sumi H, Hamada H, Nakanishi K, et al. Enhancement of the fibrinolytic activity in plasma by oral administration of nattokinase. Acta Haematologica 1990;84:139-143 (Pubitemid 20361939)
8. Katsuyama H, Ideguchi S, Fukunaga M, et al. Usual dietary intake of fermented soybeans (natto) is associated with bone mineral density in premenopausal woman. J Nutritional Science & Vitaminology 2002;48:207-215 (Pubitemid 34947914)
9. Kaneki M, Hedges SJ, Hosoi T, et al. Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2: possible implications for hip fracture risk. Nutrition 2001;17:15-321. (Pubitemid 32454984)
10. Takahashi C, Kikuchi N, Kato N, et al. Possible anti-tumor-promoting activity of components in Japanese soybean fermented food, natto: effect on gap junction intercellular communication. Carcinogenesis 1995;16:471-476
11. Okamoto A, Hanagata H, Kawamura Y, et al. Anti-hypertensive substances in fermented soybean, natto. Plant Foods for Human. Nutrition 1995;47:39-47.
12. Okamoto A, Hanagata H, Matsumoto E, et al. Angiotensin I converting enzyme inhibitory activities of various fermented foods. Bioscience, Biotechnology & Biochemistry 1995;59:1147-1149
13. Iwai K, Nakaya N, Kawasaki Y, et al. Antioxidant functions of natto, a kind of fermented soybean: effect on LDL oxidation and lipid metabolism in cholesterol-fed rats. J Agric Food Chem 2002;50:3597-3601 (Pubitemid 34579297)
14. Yokota T, Hattori T, Ohishi H, et al. The effect of antioxidant- containing fraction from fermented soybean on atherosclerosis development in cholesterol-fed rabbits. Lebensm-Wiss Technology 1996;29:751-755 (Pubitemid 126162601)
15. Weggemans RM, Trautwein EA. Relation between soy-associated isoflavones and LDL and HDL cholesterol concentrations in humans: a meta-analysis. Eur J Clin Nutr 2003;57:940-946 (Pubitemid 36987241)
16. Gardner CD, Messina M, Kiazand A, et al. Effect of two types of soy and dairy milk on plasma lipids in hypercholesterolemic adults: a randomized trial. J Am Coll Nutr 2007;26:669-677
17. Chang CT, Fan MH, Kuo FC, et al. Potent fibrinolytic enzyme from a mutant of bacillus subtilis IMR-NKl, JArgic Food Chem 2000;48:3210-3216
18. Wilson, Peter WF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847 (Pubitemid 28213628)
19. th ed. Philadephia: Saunders, 2008:1087-1088
20. Lin CY, Tsai CY, Lin SH. Effects of soy components on blood and liver lipids in rats fed high-cholesterol diets. World J Gastroenterol 2005;11:5549-5552. (Pubitemid 41684718)
21. Daiwa Pharmaceutical Co., Ltd. Cultured filtrate of natto bacilli NKCP: oral administration to human and determination of fibrinolytic activities. Tokyo, Daiwa. Pharmaceutical Company, Ltd., 2001.